Insuman Basal Solostar (Insulin Human)

Insulin Human mimics the action of naturally produced insulin by binding to insulin receptors on muscle, fat and liver cells. This triggers intracellular signaling that moves glucose‑transport proteins to the cell surface, increasing glucose uptake, while simultaneously suppressing liver glucose production, thereby lowering circulating blood sugar.

The dose of Insuman Basal Solostar is individualized. A qualified healthcare professional determines the starting amount and any subsequent adjustments based on the patient’s fasting glucose levels, overall treatment goals, body weight, renal function and other clinical factors. Patients should follow the prescriber’s written instructions precisely.

Data on the use of Insuman Basal Solostar in pregnancy and lactation are limited. It should be used only if the potential benefits to the mother outweigh any possible risks to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding must discuss treatment options with their obstetrician or endocrinologist.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and any necessary import documentation.

Insuman Basal Solostar contains human insulin, offering a relatively flat, 24‑hour profile similar to other basal analogues such as insulin glargine or detemir. While analogues may have slightly longer duration or reduced variability, human basal insulin remains effective, is often less expensive, and is compatible with standard insulin pens.

Store the prefilled pen at 2‑8 °C (refrigerated) and protect it from light. Do not freeze or shake the pen. Once in use, it may be kept at controlled room temperature (up to 30 °C) for a maximum of 28 days, as indicated on the label.

The product is supplied as a prefilled pen for subcutaneous injection. Patients should select an appropriate injection site—typically the abdomen, thigh or upper arm—rotate sites with each dose, and follow the pen’s instructions for dose setting, needle attachment and disposal.

The most serious risks include severe hypoglycemia, which can cause loss of consciousness or seizures, and allergic reactions ranging from rash to anaphylaxis. Rarely, patients may develop lipodystrophy or insulin‑binding antibodies that alter insulin effectiveness. Prompt medical attention is required if any of these events occur.

Insuman Basal Solostar is contraindicated in individuals with a known hypersensitivity to insulin human or any of the pen’s excipients. Patients with severe hypoglycemia unawareness, uncontrolled adrenal or pituitary insufficiency, or those who are unable to monitor glucose levels appropriately should avoid its use until evaluated by a clinician.